Invention Grant
- Patent Title: Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same
-
Application No.: US16311960Application Date: 2018-04-20
-
Publication No.: US11298314B2Publication Date: 2022-04-12
- Inventor: Ki Taek Lee
- Applicant: AMI PHARM CO., LTD.
- Applicant Address: KR Gyeonggi-do
- Assignee: AMI PHARM CO., LTD.
- Current Assignee: AMI PHARM CO., LTD.
- Current Assignee Address: KR Gyeonggi-do
- Agency: Leason Ellis LLP
- Priority: KR10-2017-0051868 20170421,KR10-2017-0146264 20171103
- International Application: PCT/KR2018/004642 WO 20180420
- International Announcement: WO2018/194427 WO 20181025
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K47/28 ; A61K47/10 ; A61K31/685 ; A61P3/04 ; A61K31/575

Abstract:
The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same.
The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.
The PPC injectable composition solubilized with GCA or TCA selectively reduces adipocytes without inducing necrosis of fibroblasts, muscle cells and vascular endothelial cells, thereby alleviating the known clinical side effects.
The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.
The PPC injectable composition solubilized with GCA or TCA selectively reduces adipocytes without inducing necrosis of fibroblasts, muscle cells and vascular endothelial cells, thereby alleviating the known clinical side effects.
Public/Granted literature
Information query